Sergey Sikora has over 25 years of experience in management and biomedical research, with expertise in cardiology pharmaceutical, diagnostics, and therapeutics. Sikora is the founder and former CEO of Inflamma Therapeutics, a company that is developing a leading therapeutic approach to treating a variety of autoimmune and rheumatoid conditions based on a humanized antibody-based platform that modulates a global immune response.
From 2013 to 2020, he was the CEO of CardioCell, a global biotechnology company that explores therapeutic applications of allogeneic adult stem cells for cardiovascular indications. As CEO, Sikora managed multiple clinical trials throughout the United States and internationally, and formed a scientific advisory board comprised of world-renowned key opinion leaders. Before that, Sikora held several senior-level positions at GenWay Biotech, most recently serving as senior vice president of business development. During his time at the company, Sikora established the FirstMark Cardiology Diagnostics division and grew the OEM and custom division’s revenue by more than 230% over a 2-year period. He currently serves on the board of Inflamma Therapeutics, CardioCell, and the Rady School of Management at UC San Diego. Sikora holds multiple patents and is the author of numerous peer reviewed publications, including clinical studies in cardiology. Sikora earned an MBA from the Rady School of Management at UC San Diego, a doctorate in molecular biology, and a bachelor’s degree in biochemistry, both from the University of California, Los Angeles.